Advertisement
Screener

VYOME HOLDINGS, INC. (HIND) Selling and Marketing Expense

2.8 / 5 stars · 68/120 Roast Me

VYOME HOLDINGS, INC. Selling and Marketing Expense

VYOME HOLDINGS, INC. (HIND) reported Selling and Marketing Expense of $583.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingAndMarketingExpense · last filed 2025-08-14

  • VYOME HOLDINGS, INC. selling and marketing expense for the quarter ending 2025-06-30 was $583.00K, a 12.99% decline year-over-year.
  • VYOME HOLDINGS, INC. selling and marketing expense for the quarter ending 2025-03-31 was $529.00K, a 48.09% decline year-over-year.
  • VYOME HOLDINGS, INC. selling and marketing expense for the quarter ending 2024-06-30 was $670.00K.
  • VYOME HOLDINGS, INC. selling and marketing expense for the quarter ending 2024-03-31 was $1.02M.
  • VYOME HOLDINGS, INC. selling and marketing expense for fiscal 2024 was $2.99M, a 60.37% decline from fiscal 2023.
  • VYOME HOLDINGS, INC. selling and marketing expense for fiscal 2023 was $7.55M.
Period endSelling and Marketing Expense 3 monthSelling and Marketing Expense 6 monthSelling and Marketing Expense 12 month
2025-06-30$583.00K
10-Q · filed 2025-08-14
$1.11M
10-Q · filed 2025-08-14
2025-03-31$529.00K
10-Q · filed 2025-05-20
2024-12-31$2.99M
10-K · filed 2025-04-04
2024-06-30$670.00K
10-Q · filed 2025-08-14
$1.69M
10-Q · filed 2025-08-14
2024-03-31$1.02M
10-Q · filed 2025-05-20
2023-12-31$7.55M
10-K · filed 2025-04-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36